首页> 外文OA文献 >Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor‐Positive/HER2‐Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo‐Controlled, Phase III Study (PALOMA‐3)

【2h】

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor‐Positive/HER2‐Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo‐Controlled, Phase III Study (PALOMA‐3)

机译：Palbociclib与激素受体阳性/ Her2阴性晚期转移性乳腺癌的女性联合妇女：来自多中心，随机，安慰剂控制，第三期研究的详细安全分析（Paloma-3）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Sunil Verma; Cynthia Huang Bartlett; Patrick Schnell; Angela M. DeMichele; Sherene Loi; Jungsil Ro; Marco Colleoni; Hiroji Iwata; Nadia Harbeck; Massimo Cristofanilli; Ke Zhang; Alexandra Thiele; Nicholas C. Turner; Hope S. Rugo;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3) [J] . Verma Sunil, Bartlett Cynthia Huang, Schnell Patrick, The oncologist . 2016,第10期

机译：激素受体阳性/ HER2阴性晚期转移性乳腺癌妇女中的Palbociclib与氟维西汀合用：来自多中心，随机，安慰剂对照的III期研究的详细安全性分析（PALOMA-3）
3. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3) [J] . Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, The oncologist . 2016,第10期

机译：激素受体阳性/ HER2阴性晚期转移性乳腺癌女性患者中Palbociclib与氟维西汀合用：来自多中心，随机，安慰剂对照的III期研究的详细安全性分析（PALOMA-3）
4. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 425, 2016) [J] . Cristofanilli M., Turner N. C., Bondarenko I The lancet oncology . 2016,第4期

机译：Fulvestrant加palbociclib与fulvestrant加安慰剂治疗先前接受内分泌治疗（PALOMA-3）进展的激素受体阳性，HER2阴性转移性乳腺癌：多中心，双盲，3期随机对照试验的最终分析（第17卷，第425页，2016年）
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter Randomized Placebo-Controlled Phase III Study (PALOMA-3) [O] . Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, 2016

机译：激素受体阳性/ HER2阴性晚期转移性乳腺癌妇女中的Palbociclib与氟维西汀合用：来自多中心随机安慰剂对照的III期研究的详细安全性分析（PALOMA-3）
7. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients [O] . Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, 2017

机译：paLOma-3：氟维司群有或没有palbociclib的绝经前和绝经后妇女的III期试验激素受体阳性，人类表皮生长因子受体2 - 先前内分泌治疗进展的阴性转移性乳腺癌 - 亚洲患者的安全性和有效性

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor‐Positive/HER2‐Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo‐Controlled, Phase III Study (PALOMA‐3)

著录项

相似文献

相关主题

期刊订阅